CEO Executive AssistantPharmaceutical organizations operate in one of the most regulated, capital-intensive, and risk-laden industries in the global economy. As CEO, you are accountable not only for financial performance but for patient safety, regulatory standing, and the integrity of every product that carries your organization’s name. This checklist covers the operational domains that demand CEO-level attention and standards.
Use this as a structured review tool when assessing organizational health, preparing for board updates, or conducting your own quarterly operations audit. Gaps in any domain represent compounding risk: regulatory, financial, reputational, and patient safety consequences do not wait for a convenient moment.
Regulatory and Compliance Operations
Regulatory compliance is not a department function in pharma; it is a company-wide standard of conduct. The FDA, EMA, and other regulatory bodies hold the CEO accountable for the compliance culture of the organization.
Key items to verify:
- A Chief Compliance Officer or VP of Regulatory Affairs reports with a clear line to you and has defined authority to escalate issues directly
- A regulatory intelligence function monitors rule changes, guidance documents, and enforcement actions relevant to your products and markets
- Inspection readiness is maintained year-round, not activated only when an inspection is announced
- All manufacturing facilities have current, compliant master batch records and standard operating procedures
- A documented CAPA (Corrective and Preventive Action) system is active, with metrics reviewed at least monthly
- Adverse event reporting timelines are tracked against regulatory requirements with no systemic backlogs
- A regulatory submission calendar is maintained with ownership and milestone tracking
- All third-party manufacturers, contract research organizations, and distribution partners are qualified and audited on a documented schedule
CEO action: If your organization only prepares for inspections when notified, you are managing compliance as a performance rather than a culture. Real-time readiness requires investment in systems, training, and leadership accountability.
Manufacturing and Quality Operations
Manufacturing quality is the most direct expression of your commitment to patients. For a deeper review of this area, see pharma CEO operations for a comprehensive framework.
Key items to verify:
- A qualified VP of Manufacturing or SVP of Operations owns production performance with defined KPIs
- Batch rejection rates are tracked and trended monthly, with root cause analysis for any out-of-specification events
- Equipment qualification, calibration, and maintenance schedules are current and documented
- Environmental monitoring results for sterile and controlled manufacturing areas are reviewed by quality leadership at least monthly
- A validated change control process governs all modifications to processes, equipment, and materials
- Supply chain risk is assessed formally, with documented alternatives for critical raw materials and API sources
- Yield and cycle time metrics are reviewed at least quarterly against benchmarks
- Product release timelines are tracked against targets, with escalation triggers defined
CEO action: Manufacturing operations require you to hold a high standard on quality metrics before financial metrics. A batch that ships out of specification is a liability that no revenue target can offset.
Research and Development Operations
R&D is the engine of your pipeline, and pipeline health is the most direct predictor of long-term organizational value. Operational discipline in R&D is often underdeveloped because research cultures resist process.
Key items to verify:
- A gated stage-gate review process governs pipeline advancement decisions
- Portfolio prioritization criteria are documented and applied consistently across programs
- R&D spend is tracked against approved budgets by program and by stage
- Clinical trial operations have defined governance, including a safety monitoring committee for each active study
- Data management and biostatistics resources are adequate for the number of active programs
- Intellectual property (IP) strategies are reviewed by outside counsel at least annually
- Technology transfer processes from research to development and from development to manufacturing are documented
- Innovation partnerships, licensing agreements, and academic collaborations have assigned relationship owners and tracking mechanisms
CEO action: Pipeline decisions made without rigorous go/no-go criteria tend to survive on momentum rather than merit. Require evidence-based portfolio reviews and resist the organizational pressure to continue programs past their strategic justification.
Commercial Operations
Commercial performance depends on the quality of your launch readiness, market access strategy, and field execution. Operational gaps in commercial functions directly affect revenue and patient access.
Key items to verify:
- A commercial operations leader owns launch planning with a documented timeline at least 18 months before anticipated approval
- Market access and payer strategy is developed in parallel with regulatory strategy, not after
- Field force sizing and deployment models are reviewed annually with market data
- A CRM system captures field activity, call reporting, and key account management with consistent adoption
- Medical affairs and commercial operate with clear, documented boundaries on the scientific exchange and promotional activities
- Distribution and logistics partners are managed with service level agreements and performance reviews
- Named patient and compassionate use programs are administered with clear SOPs and compliance oversight
- Revenue forecasting models are reviewed for assumptions at least quarterly
CEO action: Launch failures are almost always operational failures in disguise. Product quality may be excellent, but if market access, field readiness, or logistics are underprepared, the commercial outcome will not reflect the science.
Finance and Business Operations
Financial discipline in pharma must account for the long-cycle nature of drug development, the front-loaded cost structure of clinical programs, and the regulatory risk that can render investments worthless.
Key items to verify:
- R&D capitalization and expense policies are current and consistently applied
- Program-level P&L reporting exists for all commercial-stage products
- A formal capital allocation framework governs investment decisions across pipeline, commercial, and infrastructure
- Cash runway projections are updated monthly and reviewed by the board at least quarterly
- A qualified CFO owns investor relations with direct access to you and the board
- Contract manufacturing and research agreements are reviewed for financial terms at least annually
- Tax strategies, transfer pricing policies, and government incentive programs are reviewed annually by outside advisors
- Foreign exchange and interest rate exposures are identified, quantified, and managed
CEO action: Many pharma organizations operate with excellent clinical discipline and poor financial discipline. Both matter. Insist on the same rigor in financial planning that you expect in clinical protocol design.
Human Resources and Talent Operations
Pharmaceutical talent markets are highly specialized and nationally competitive. Losing a critical scientific or regulatory leader can set a program back by 12 to 18 months.
Key items to verify:
- A succession plan exists for all director-level and above positions, reviewed annually
- Compensation benchmarking uses pharma-specific surveys (not general industry benchmarks)
- Scientific career tracks exist so technical experts are not required to move into management to advance
- Key person retention plans (equity, deferred compensation, project milestones) are in place for critical staff
- Onboarding for GMP-relevant roles includes documented training completion before job function commencement
- Annual training requirements for all staff are tracked in a learning management system (LMS)
- Organizational design is reviewed at least annually to ensure structure supports current strategy
CEO action: In pharma, people are the pipeline. Talent operations are not an HR function; they are a strategic function that requires CEO investment and attention.
Information Technology and Data Integrity
IT systems in pharma carry regulatory weight. Data integrity violations have resulted in warning letters, consent decrees, and product withdrawals.
Key items to verify:
- All computer systems used in GxP-relevant activities are validated per applicable regulations (21 CFR Part 11 or equivalent)
- Audit trails are enabled and protected in all regulated systems
- A master data integrity policy exists and is incorporated into training for all relevant staff
- Cybersecurity protocols protect proprietary research data, manufacturing formulas, and clinical trial information
- Enterprise systems (ERP, LIMS, QMS) have documented access controls reviewed annually
- Technology vendors with access to regulated data are qualified and monitored under formal agreements
- A data governance policy defines ownership, quality standards, and lifecycle management for critical organizational data
CEO action: Data integrity is not an IT issue; it is a product quality issue. Treat it with the same seriousness as manufacturing quality.
Legal, Ethics, and Government Affairs
The legal and ethical operating environment for pharmaceutical companies is continuously evolving and highly scrutinized.
Key items to verify:
- A Chief Legal Officer or General Counsel has direct access to you and a seat at leadership team meetings
- A healthcare compliance program addresses anti-kickback, promotional compliance, and government pricing obligations
- All clinical research is conducted under a current, approved IRB protocol
- Patent strategies are reviewed annually to assess exposure and opportunity
- Relationships with government and legislative bodies are managed by a dedicated or contracted government affairs function
- A code of conduct is signed annually by all staff and reviewed for currency at minimum every two years
- An ethics hotline is operational, independent, and reviewed by the audit committee
CEO action: Legal and ethical exposure in pharma tends to accumulate quietly. Require your legal and compliance leadership to brief you monthly on current issues and emerging risks, not just at formal reviews.
Operational Cadence and Executive Rhythm
A checklist is a starting point, not a management system. The value is in establishing a regular operating rhythm that addresses each domain on a defined schedule.
Pharma ops efficiency strategies can provide a framework for prioritizing where to focus improvement efforts given your organizational stage and strategic priorities.
Research from McKinsey on biopharma operating models confirms that companies with disciplined operating rhythms and clear accountability structures consistently outperform on both pipeline productivity and commercial execution.
As CEO, you do not need to personally manage every domain on this checklist. You need to ensure every domain has a qualified owner, a defined standard, and a reporting mechanism that gives you early warning when performance deviates. Build that system and your organization will be positioned to execute at the level this industry demands.
Related Reading
For further context, explore Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide and Antibiotics Pipeline Pharma CEO Business Operations Guide.